Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 261 to 270 of 281 total matches.
Istradefylline (Nourianz) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
such as
pathologic gambling, hypersexuality, and binge eating.
DRUG INTERACTIONS — Istradefylline is metabolized ...
The FDA has approved istradefylline (Nourianz —
Kyowa Kirin), an oral adenosine A2A receptor antagonist,
for use as an adjunct to carbidopa/levodopa in adults
with Parkinson's disease (PD) who experience "off"
episodes. Istradefylline is the first adenosine A2A
receptor antagonist to be approved in the US; it has
been available in Japan since 2013.
Opdualag for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
of melanoma.
T-cell exhaustion. Nivolumab binds to PD-1, blocking
interaction of the receptor with its ...
Opdualag (BMS), a fixed-dose combination of two
immune checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab-rmbw, a lymphocyte-activation gene-3
(LAG-3) blocking antibody — has been approved by
the FDA for treatment of unresectable or metastatic
melanoma in patients ≥12 years old. Relatlimab, which
is only available in combination with nivolumab, is
the first LAG-3 blocking antibody to become available
in the US. Immune checkpoint inhibitors, including
the anti-CTLA-4 antibody ipilimumab (Yervoy) and
the PD-1 inhibitors...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e19-20 doi:10.58347/tml.2023.1668g | Show Introduction Hide Introduction
COVID-19 Update: Prescription of Paxlovid by Pharmacists (online only)
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
) for Paxlovid (Pfizer), the investigational oral antiviral drug nirmatrelvir copackaged with oral ritonavir ...
The FDA has amended its Emergency Use Authorization (EUA) for Paxlovid (Pfizer), the investigational oral antiviral drug nirmatrelvir copackaged with oral ritonavir, to allow for it to be prescribed by licensed pharmacists in certain situations. Paxlovid is authorized for oral treatment of mild to moderate COVID-19 in high-risk outpatients ≥12 years old who weigh at least 40 kg. NIH guidelines list it as the treatment of choice for COVID-19 in high-risk adult outpatients.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
symptoms.
DRUG INTERACTIONS — Use of opioids with alcohol,
general anesthetics, phenothiazines ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
In Brief: A New Endometrial Cancer Indication for Dostarlimab (Jemperli) (online only)
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
to PD-1 on T cells,
blocking its interaction with PD-L1 and PD-L2 and
restoring T-cell antitumor ...
The immune checkpoint inhibitor dostarlimab-gxly
(Jemperli – GSK) has been approved by the FDA for
use in combination with carboplatin and paclitaxel
for treatment of adults with mismatch repair deficient
(dMMR) or microsatellite instability-high (MSI-H)
primary advanced or recurrent endometrial cancer.
Dostarlimab was recently granted regular approval
for treatment of adults with dMMR recurrent or
advanced endometrial cancer that progressed on
or following a prior platinum-containing regimen in
any setting and who are not candidates for curative
surgery or radiation.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e138 doi:10.58347/tml.2023.1683f | Show Introduction Hide Introduction
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
not be
started ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
approval of the drug was based on the response rate
and duration of response. Retifanlimab is the third ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1) blocking antibody, has
received accelerated approval from the FDA for
treatment of metastatic or recurrent locally advanced
Merkel cell carcinoma (MCC) in adults. Accelerated
approval of the drug was based on the response rate
and duration of response. Retifanlimab is the third
drug to be approved in the US for treatment of MCC;
pembrolizumab (Keytruda), a PD-1 blocking antibody,
is approved for the same indication as retifanlimab
in patients ≥12 years old and avelumab (Bavencio),
a programmed death...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e73-4 doi:10.58347/tml.2023.1674h | Show Introduction Hide Introduction
In Brief: Oritavancin (Kimyrsa) for Skin and Skin Structure Infections (online only)
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
such as pruritus, urticaria,
and flushing have also been reported.
DRUG AND LABORATORY TEST INTERACTIONS ...
The FDA has approved Kimyrsa (Melinta), a new
IV formulation of the long-acting lipoglycopeptide
antibiotic oritavancin, for treatment of adults with acute
bacterial skin and skin structure infections caused by
susceptible gram-positive bacteria. Orbactiv (Melinta),
another IV formulation of oritavancin, was approved in
2014 for the same indication. Kimyrsa has a smaller
infusion volume (250 mL vs 1 L) and a shorter infusion
time (1 hour vs 3 hours) compared to Orbactiv (see
Table 1).
Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
). Atezolizumab is
the first drug to be approved in the US for treatment
of ASPS. ASPS is a rare disorder ...
Atezolizumab (Tecentriq – Genentech), an immune
checkpoint inhibitor, has been approved by the FDA
for treatment of unresectable or metastatic alveolar
soft part sarcoma (ASPS) in patients ≥2 years old. It
was previously approved for treatment of non-small
cell lung cancer, small cell lung cancer, hepatocellular
cancer, and melanoma (see Table 1). Atezolizumab is
the first drug to be approved in the US for treatment
of ASPS. ASPS is a rare disorder that affects mostly
adolescents and young adults; <1% of soft tissue
sarcomas are ASPS.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e56-7 doi:10.58347/tml.2023.1673d | Show Introduction Hide Introduction
Bimekizumab (Bimzelx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
expensive
than other oral drugs, but it increases the risk of
infection and can cause serious hematologic ...
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx
– UCB) for treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
treatment or phototherapy. Bimekizumab is the first
IL-17A/17F antagonist to be approved in the US. It
was approved in the European Union for the same
indication in 2021.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):11-3 doi:10.58347/tml.2024.1694b | Show Introduction Hide Introduction